STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

ARWR ARROWHEAD PHARMACEUTICALS INCORPORATED StockScouter® Report

4

StockScouter® Score

ARROWHEAD PHARMACEUTICALS INCORPORATED, a mid cap growth company in the healthcare sector, is expected to perform in line with the market over the next six months with average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • One or more analysts has significantly increased quarterly earnings estimates for ARWR. Positive
  • Moving average analysis for ARWR suggests flat price movement over the medium term. Neutral

 

Concerns

  • The most recent quarterly earnings report was significantly lower than analysts’ consensus forecast. Negative
  • The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that mid cap stocks will be neutral, growth stocks will be neutral, and healthcare stocks will be neutral.

Expected Risk/Return

Progress: 60% done.
Progress: 60% done.
Low
High

Core Model Grades

C
C
F
D

Previous Ratings

2
2
3